Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms
This open-label, dose escalation and cohort expansion trial has been designed to determine the safety, tolerability, PK, PD, immunogenicity and antitumour activity of MGD013, administered by IV infusion every 2 weeks. In the Dose Escalation Phase, MGD013 will be evaluated in sequential escalating flat doses in successive cohorts of 1 to 6 patients each. Upon completion of the Dose Escalation Phase, a Cohort Expansion Phase will be initiated at the MTD/MAD.